View Post

Biotheranostics’ Breast Cancer Index® predicts benefit from two-and-a-half versus five years of extended endocrine therapy in HR+ breast cancer patients treated in the IDEAL trial

In Clinical Studies News by Barbara Jacoby

Source: Biotheranostics, Inc. From: Novel evidence demonstrating the ability of Breast Cancer Index to predict preferential endocrine response in distinct subgroups of HR+ early stage breast cancer patients will be premiered at ASCO 2020.  The Investigation on the Duration of Extended Adjuvant Letrozole (IDEAL) trial examined the Breast Cancer Index (BCI) HOXB13/IL17BR ratio (H/I) and its ability to predict …